Acquisition of china bio-tech is complete and now the newest news is the Board of Directors is set.... get ready for more good stuff, and blast off to 50cents easy...
Waterford Sterling Names Experts in Embryo Biotechnology, Animal Genomics, Medic
/FROM PR NEWSWIRE MIAMI 305-461-8666/
TO BUSINESS AND MEDICAL EDITORS:
Waterford Sterling Names Experts in Embryo Biotechnology, Animal Genomics,
Medicine and Management to Board of Directors
WINTER PARK, Fla., June 6 /PRNewswire-FirstCall/ --
Waterford Sterling Corporation (OTC Bulletin Board: WTFD) released today the
names of its new Board of Directors drawn from experts in embryonic
biotechnology, animal genomics and medical/business management. The Board is
expected to be very proactive in helping the Company achieve its ambitious
goals.
The new Board of Directors will be:
Mr. Jijun Wu, Chairman
Mr. Wu graduated from China Central Finance & Economics University. Mr. Wu
became one of the first CPAs in the People's Republic of China. He has
significant experience in finance and investments and has held the position of
Accountant-General in a state-owned electronics company with revenues of over
$1.5 billion and over 200 subsidiaries. Mr. Wu maintains business
relationships with more than twenty major banks, consortiums and funds
worldwide. Mr. Wu took a lead in planning for mainland enterprises to list on
overseas stock markets. He was the consultant to Motorola, NEC, Epson, Yamaha,
AT&T, and Panasonic when they initiated investments in the PRC in the early
1980s. He was made an honorary citizen of Houston, TX.
Mr. Jiansheng Wei, Director
Mr. Wei graduated with an MBA from Tianjin Finance & Economics College.
He has been engaged in animal husbandry practices and management for over
thirty years and has been in charge of several large farms in Inner Mongolia
and Hebei Province. He is familiar with advanced husbandry techniques and has
significant experience in management, breeding and the introduction of
superior agricultural genetics. Mr. Wei maintains close commercial
relationships within animal husbandry and business circles throughout
Southeast Asia, Australia, New Zealand and South Africa.
Dr. Thomas E. Wagner, Director
Dr. Wagner is currently the Director of the Oncology Research Institute at
the Greenville Hospital System and Distinguished Professor of Molecular &
Cellular Biology at Clemson University. He was trained in both the physical
biochemistry of DNA and microbiology at Princeton and Northwestern University,
where he received his PhD. He carried out research on the conformational
changes in DNA associated with gene expression since the early 1970s.
His research laboratory performs studies of early development including
embryonic microsurgery and contemporary molecular biology including complex
RT/PCR cloning. This has led to contributions including the development of the
means of producing transgenic animals in 1979, the isolation and maintenance
in culture of embryo-derived stem cell populations useful in transplantation
biology and medicine, as well as vehicles for cell-based gene therapy in 1987
and the development of a highly efficient cytoplasmic T7 gene therapy vector
in 1993. Since 1998 he has focused his efforts as Director of the Oncology
Research Institute on the application of modern molecular and cellular biology
to the development of new therapies for the treatment of cancer.
His work has been presented in 203 publications. Dr. Wagner has filed over
thirty patents and, to date, received eight patents on his work. He is also
currently: Senior Examiner and Consultant, Research Grants Council, Hong Kong;
Advisor and Honorary Professor of Molecular Biology, Tsing Hua University,
Beijing; and Honorary Professor of Biology, National Hydrobiology Institute,
Chinese Academy of Sciences, Wuhan, China.
Mr. Shien Zhu, Director
Mr. Zhu holds post-doctoral, Associate Professor and Master Director
positions with several leading Chinese universities. As a doctor from Kochi
University and Ehime University in Japan, he majored in the area of early
embryo vitrification freezing and transfer and of mammal adoscuolation in
embryo biotechnology. He invented a system of freezing and preservation,
unaided by a cooling frigorimeter, which is characterized by low cost, simple
operation and a high embryonic survival rate. In recent years, he has written
more than forty articles that were published in international and domestic
periodicals. Currently, he is undertaking vital "863" projects for the PRC and
scientific research projects under the "Ninth Five-Year Plan" period.
Mr. James Q. Wang, Director
Mr. Wang, a Canadian citizen, received a Master of Applied Science degree
from the University of Ottawa. He has gained exceptional expertise in
enterprise management, marketing and engineering due to his leadership roles
in the telecommunications, electronics and Internet industries.
Before joining Eternal, Mr. Wang founded DNS Technologies Group Inc.
(Canada) and served as its President. DNS specialized in Internet technologies
and outsourcing between North America and Asia. Mr. Wang started his career
first as an engineer in NEC, where he published his technical innovation
proposal and was honored with an Award of Excellence at NEC's headquarters in
Tokyo. Later, he moved to the NEC Marketing department in charge of
sales/marketing for the entire Eastern region of mainland China.
About Eternal Technology Group
Eternal Technology Group Ltd. is a major agricultural genetics and
bio-pharmaceutical R&D firm operating in China with the support of the Chinese
Government. Eternal's animal breeding and human medicines divisions are
profitable with a strong asset base, cash position and net income.
For more information go to http://www.waterfordsterling.com or call Jacob
Nguyen at (407) 622-2040.
Safe Harbor Statement under the Private Securities Litigation Reform Act
of 1995: The statements in the press release that relate to the company's
expectations with regard to the future impact on the company's results from
new products in development are forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. The results
anticipated by any or all of these forward-looking statements may not occur.
MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X99393778
SOURCE Waterford Sterling
/CONTACT: Jacob Nguyen of Waterford Sterling, +1-407-622-2040/
/Web site: http://www.waterfordsterling.com /
Jun-06-2002 16:33 GMT
Symbols:
US;WTFD
Source PRN PR NewsWire
Categories:
NWR/FL NWI/MTC NWI/OTC NWS/PER MST/R/CN MST/R/JP MST/R/US/FL
MST/I/DRG MST/I/MKT MST/S/PER
News 
Market Data 
Discover 
